Torrent Pharmaceuticals Ltd reported a 27 per cent decline in profit after tax to Rs 364 crore for the fourth quarter ended March 31, 2026, weighed down by exceptional items, even as revenues continued to grow strongly. The company had posted a net profit of Rs 498 crore in the same quarter of the previous fiscal, it said in a statement.
Revenue from operations in Q4 FY26 rose to around Rs 4,197 crore, driven by growth across key markets, including India, Brazil and the US, and the integration of its acquired JB Pharma portfolio. However, higher costs associated with acquisitions, integration and other exceptional charges compressed profitability despite the top-line expansion.
For the full year FY26, Torrent Pharma reported a performance improvement, with net profit increasing to Rs 2,138 crore compared with Rs 1,911 crore in FY25, reflecting the benefits of scale from its expanded portfolio. Consolidated revenue for the year rose 21 per cent to Rs 13,980 crore, supported by strong growth in branded generics and international markets.
Analysts noted that while March-quarter earnings were impacted by one-off items and elevated expenses, the underlying business momentum remains healthy, aided by the JB integration and continued strength in core markets. The company has indicated that it will focus on further synergies from recent acquisitions and disciplined cost management to support margin recovery in the coming quarters.
